|
References Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh Iii EE (1993) Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. Stroke 24:35-41. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Sacco RL, Schwamm LH, American Heart A and American Stroke A (2008) Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39:1647-1652. Albers GW (2000) Choice of endpoints in antiplatelet trials. Which outcomes are most relevant to stroke patients? Neurology 54:1022-1028. Albers GW, Amarenco P, Easton JD, Sacco RL and Teal P (2008) Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:630S-669S. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL and Sherman DG (2002) Transient ischemic attack - Proposal for a new definition. New England Journal of Medicine 347:1713-1716. Algra A and Van Gijn J (1996) Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. Journal of Neurology Neurosurgery and Psychiatry 60:197-199. Appelros P, Nydevik I and Viitanen M (2003) Poor outcome after first-ever stroke: Predictors for death, dependency, and recurrent stroke within the first year. Stroke 34:122-126. Ariesen MJ, Algra A and Kappelle LJ (2006) Antiplatelet drugs in the secondary prevention after stroke: Differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 37:134-138. Armstrong, AW and Golan, DE (2005) Pharmacology of Hemostasis and Thrombosis in Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, Second Edition, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, P.335-356. Badjatia N and Rosand J (2005) Intracerebral hemorrhage. Neurologist 11:311-324. Baigent C, Sudlow C, Collins R and Peto R (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 324:71-86. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ and Fox KAA (2007) Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology 49:1982-1988. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J and Topol EJ (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine 354:1706-1717. Brott T, Adams Jr HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ and Walker M (1989) Measurements of acute cerebral infarction: A clinical examination scale. Stroke 20:864-870. Chen ZM (1997) CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641-1649. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG and Romano JG (2005) Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New England Journal of Medicine 352:1305-1316. Connolly SJ, Pogue J, Chrolavicius S, Hart R, Pfeffer M, Hohnloser S and Yusuf S (2009) Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 360:2066-2078. Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR and Eisert W (2005) Dipyridamole bioavailability in subjects with reduced gastric acidity. Journal of Clinical Pharmacology 45:845-850. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P and Lowenthal A (1996) European stroke prevention study 2 (ESPS-2). Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences 143:1-13. Diener PHC, Bogousslavsky PJ, Brass PLM, Cimminiello PC, Csiba PL, Kaste PM, Leys PD, Matias-Guiu PJ and Rupprecht PHJ (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 364:331-337. Dong HS, Phil HL and Oh YB (2005) Mechanisms of recurrence in subtypes of ischemic stroke: A hospital-based follow-up study. Archives of Neurology 62:1232-1237. Easton JD (1998) Erratum: Benefit of clopidogrel in patients with evidence of cerebrovascular disease. Neurology 51:332. Eisert WG (2001) Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 57:S20-S23 Fagan SC and Hess DC (2008) Stroke in Pharmacotherapy: A Pathophysiologic Approach, Seventh Edition, McGraw-Hill Medical, New York, P.373-384. Gent M (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV and Sacco RL (2006) Primary prevention of ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council. Stroke 37:1583-1633. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W and Diener HC (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: The German stroke data bank. Stroke 32:2559-2566. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ and Algra A (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367:1665-1673. Helgason CM and Wolf PA (1997) American Heart Association Prevention Conference IV: Prevention and Rehabilitation of Stroke: Executive summary. Circulation 96:701-707. Hu HH, Chu FL, Chiang BN, Lan CF, Sheng WY, Lo YK, Wong WJ and Luk YO (1989) Prevalence of stroke in Taiwan. Stroke 20:858-863. Jeng JS, Lee TK, Chang YC, Huang ZS, Ng SK, Chen RC and Yip PK (1998) Subtypes and case-fatality rates of stroke: A hospital-based stroke registry in Taiwan (SCAN-IV). Journal of the Neurological Sciences 156:220-226. Johnston SC, Gress DR, Browner WS and Sidney S (2000) Short-term prognosis after emergency department diagnosis of TIA. Journal of the American Medical Association 284:2901-2906. Juvela S and Kase CS (2006) Advances in intracerebral hemorrhage management. Stroke 37:301-304. Kitamura A, Nakagawa Y, Sato M, Iso H, Sato S, Imano H, Kiyama M, Okada T, Okada H, Iida M and Shimamoto T (2006) Proportions of stroke subtypes among men and women > or = 40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke 37:1374-1378. Knapp M, King D, Pugner K and Lapuerta P (2004) Non-adherence to antipsychotic medication regimens: Associations with resource use and costs. British Journal of Psychiatry 184:509-516. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B and Heuschmann PU (2001) Epidemiology of ischemic stroke subtypes according to TOAST criteria: Incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study. Stroke 32:2735-2740. Liao JK (2007) Secondary prevention of stroke and transient ischemic attack: Is more platelet inhibition the answer? Circulation 115:1615-1621. Lovett JK, Coull AJ and Rothwell PM (2004) Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62:569-573. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams Jr HP, Jackson CM and Pullicino P (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New England Journal of Medicine 345:1444-1451. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH and Folsom AR (2006) Risk factors for ischemic stroke subtypes: The atherosclerosis risk in communities study. Stroke 37:2493-2498. Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O''Fallon WM and Wiebers DO (1999) Ischemic stroke subtypes: A population-based study of incidence and risk factors. Stroke 30:2513-2516. Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O''Fallon WM and Wiebers DO (2000) Ischemic stroke subtypes: A population-based study of functional outcome, survival, and recurrence. Stroke 31:1062-1068. Piette JD, Heisler M and Wagner TH (2004) Problems Paying Out-of-Pocket Medication Costs among Older Adults with Diabetes. Diabetes Care 27:384-391. Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S and Connolly SJ (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903-1912. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O''Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M and Hong Y (2008) Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25-e146. Rothwell PM and Warlow CP (2005) Timing of TIAs preceding stroke: Time window for prevention is very short. Neurology 64:817-820. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH and Tomsick T (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association council on stroke - Co-sponsored by the council on cardiovascular radiology and intervention. The American Academy of Neurology affirms the value of this guideline. Stroke 37:577-617. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BPL, Chen ST, Cunha L, Dahlo?f B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vander Maelen C, Voigt T, Weber M and Yoon BW (2008) Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine 359:1238-1251. Sandercock PAG (1997) The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 349:1569-1581. Sarasin FP, Gaspoz JM and Bounameaux H (2000) Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Archives of Internal Medicine 160:2773-2778. Savi P, Heilmann E, Nurden P, Laplace MC, Bihour C, Kieffer G, Nurden AT and Herbert JM (1996) Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clinical and Applied Thrombosis/Hemostasis 2:35-42. Savi P, Laplace MC, Maffrand JP and Herbert JM (1994) Binding of [3H]-2-methylthio ADP to rat platelets - Effect of clopidogrel and ticlopidine. Journal of Pharmacology and Experimental Therapeutics 269:772-777. Schulz UGR and Rothwell PM (2003) Differences in vascular risk factors between etiological subtypes of ischemic stroke: Importance of population-based studies. Stroke 34:2050-2059. Steg G, Bhatt DL, Wilson PWF, D''Agostino Sr R, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ and Goto S (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. Journal of the American Medical Association 297:1197-1206. Theis JGW, Deichsel G and Marshall S (1999) Rapid development of tolerance to dipyridamole-associated headaches. British Journal of Clinical Pharmacology 48:750-755. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O''Donnell C, Kittner S, Lloyd-Jones D, Goff Jr DC and Hong Y (2006) Heart disease and stroke statistics - 2006 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:e85-e151. Tseng CH, Chong CK, Sheu JJ, Wu TH and Tseng CP (2005) Prevalence and risk factors for stroke in Type 2 diabetic patients in Taiwan: A cross-sectional survey of a national sample by telephone interview. Diabetic Medicine 22:477-482. Uchino K, Risser JMH, Smith MA and Morgenstern LB (2004) Ischemic stroke subtypes among Mexican Americans and non-Hispanic whites: The BASIC project. Neurology 63:574-576. Van Latum JC, Vermeulen PC, Den Ouden A, Mast B, Koudstaal PJ, Bogousslavsky J, Boysen G, Bornstein N, Candelise L, Dahl T, Dehaene I, Ferro J, Van Gijn J, Gustafsson C, Hedenus M, Hijdra A, Kramer G, Lodder J and Mas JL (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA and Van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604-607. Vane JR and Botting RM (2003) The mechanism of action of aspirin. Thrombosis Research 110:255-258. Warlow (1991) The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. Journal of Neurology Neurosurgery and Psychiatry 54:1044-1054. Warlow C (1992) Secondary prevention of stroke. Lancet 339:724-727. Wolf PA (2003) Fifty years at Framingham: contributions to stroke epidemiology. Advances in neurology 92:165-172. Yip PK, Jeng JS, Lee TK, Chang YC, Huang ZS, Ng SK and Chen RC (1997) Subtypes of ischemic stroke: A hospital-based stroke registry in Taiwan (SCAN-IV). Stroke 28:2507-2512. 中華民國行政院衛生署 (2008) 97年死因統計結果分析 Available at: http://www.doh.gov.tw/ 台灣腦中風學會 (2009) Available at: http://www.stroke.org.tw/
|